NASD · Healthcare · Biotechnology · USA
MeiraGTx Holdings plc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company with programs for conditions including radiation-induced xerostomia, Parkinson's disease, and retinal dystrophy. The company operates vertically integrated manufacturing facilities in London and Shannon for producing viral vectors and plasmid DNA for genetic therapies. It also develops a proprietary riboswitch platform technology for controlling gene expression through oral small molecules.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the MeiraGTx Holdings plc stock.
Undervalued: intrinsic value $35.58 per share, market price $9.49, margin of safety 73.3% (as of 2026-10-30).
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $35.58; the price of $9.49 is 73% below that value, and 75% of that value comes from beyond year five.
Leak Score: 64/100 on 10 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
MGTX is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $35.58; the price of $9.49 is 73% below that value, and 75% of that value comes from beyond year five.
$35.58 per share (as of the 2026-10-30 close), against a market price of $9.49. That is a margin of safety of 73.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
64 out of 100, which we rate "Faint Leak", on 10 of 12 value investing signals.